UCB Japan said on March 15 that it has filed a new 320 mg auto-injector version of its psoriasis treatment Bimzelx (bimekizumab) in Japan. A humanized monoclonal IgG1 antibody, Bimzelx was launched in the country in April 2022 and is…
To read the full story
Related Article
- Bimzelx Now Available as Single-Injection Option: UCB Japan
May 30, 2025
- UCB Bags Japan Approval for Bimzelx’s 320 mg Auto-Injector
February 7, 2025
- Lumakras, Bimzelx, Pivlaz Now Available in Japan
April 21, 2022
BUSINESS
- Takeda CEO Says Orzeyful Could Redefine NT1 Standard of Care
July 31, 2026
- Pfizer Seeks Pediatric Expansion for Hympavzi in Japan
July 31, 2026
- Nippon Shinyaku Exercises Option for AB2 Bio’s Tadekinig Alfa in US
July 31, 2026
- Alfresa Takes Stake in Ember to Bolster Pharma Cold Chain in Japan
July 31, 2026
- Sanwa Kagaku Says Kumamoto Plant Remains Shut, Drug Supplies Stable
July 31, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…





